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AB-type protein toxins such as cholera toxin (CT) consist of a catalytic A subunit 
and a cell-binding B subunit.  CT proceeds through the secretory pathway in reverse, 
termed retrograde trafficking, and is delivered to the endoplasmic reticulum (ER).  In 
order for the catalytic A1 subunit to become active it must separate from the rest of the 
holotoxin, and this dissociation event occurs in the ER lumen.  CTA1 assumes an 
unfolded conformation upon dissociation from the holotoxin and is recognized by ER- 
associated degradation (ERAD), a quality control system that recognizes and exports 
misfolded proteins to the cytosol for degradation by the 26S proteasome.  CTA1 is not 
degraded by the 26S proteasome because it has few sites for poly-ubitiquination, which 
is recognized by the cap of the 26S proteasome for degradation. Thus, CTA1 escapes 
the degradation of ERAD while at the same time using it as a transport mechanism into 
the cytosol. 
It was originally proposed that CTA1 is thermally stable and that ER chaperones 
actively unfolded CTA1 for translocation to the cytosol.  In contrast, we hypothesized 
that the dissociated CTA1 subunit would unfold spontaneously at 37°C.   This study 
focused on the three conditions linked to CTA1 instability and translocation: (i) CTA1 
dissociation from the holotoxin, (ii) the translocation-competent conformation of CTA1, 
and (iii) the extraction of CTA1 from the ER into the cytosol.  Disruption of any of these 
events will confer resistance to the toxin.  The original model suggested that PDI 
actively unfolds CTA1 to allow for translocation. However, Fourier transform infrared 
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spectroscopy (FTIR) and surface plasmon resonance (SPR) data we have gathered 
demonstrated that PDI dislodges CTA1 from the rest of the holotoxin without unfolding 
CTA1.  Once released by the holotoxin, CTA1 spontaneously unfolds.  PDI is thus 
required for the toxicity of CT, but not as an unfoldase as originally proposed.  CTA1 
must maintain an unfolded conformation to keep its translocation-competent state.  
Based on our model, if CTA1 is stabilized then it will not be able to activate the ERAD 
translocation system.  Our SPR and toxicity results demonstrated that treatment with 4-
phenylbutyrate (PBA), a chemical chaperone, stabilizes the structure of CTA1.  This 
stabilization resulted in a decrease in translocation from the ER to the cytosol and a 
block of intoxication, which makes it a viable candidate for a therapeutic.  Because 
CTA1 exits the ER in an unfolded state, there must be a driving force for this 
translocation.  We hypothesized that Hsp90, a cytosolic chaperone, is responsible for 
the translocation of CTA1 across the membrane.  Previous research had shown Hsp90 
to be present on the cytosolic face of the ER and had also shown that Hsp90 will refold 
exogenously added proteins that enter the cytosol.  Using drug treatments and RNAi, 
we found that Hsp90 is required for the translocation of CTA1 from the ER lumen to the 
cytosol, a brand new function for this chaperone. 
We have provided evidence to support a new, substantially different model of 
CTA1 translocation.  CTA1 does not masquerade as a misfolded protein in order to 
utilize ERAD for entry into the cytosol; it actually becomes misfolded and is treated as 
any other ERAD substrate.  The spontaneous unfolding of CTA1 is the key to its 
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recognition by ERAD and ultimately its translocation into the cytosol.  Host factors play 
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CHAPTER 1 INTRODUCTION 
1.1 Intracellular Trafficking 
 
Cells must use several endocytic paths in order to carry out many different 
functions.  The most well known of these mechanisms involves clathrin-coated 
pits and vesicles (1, 2).  Clathrin-dependent endocytosis is used to acquire 
nutrients from the extracellular environment.  This type of endocytosis occurs on 
special coated pits localized on the plasma membrane.  Ligands from the 
extracellular environment bind via specific cell-surface receptors that trigger a 
signaling cascade to recruit clathrin to the cytosolic face of the plasma 
membrane.  When clathrin is recruited to the plasma membrane it binds to other 
clathrin molecules creating a mesh underlying the ligand receptor complex and 
causing the plasma membrane to invaginate and pinch off.  In addition to 
clathrin-dependent endocytosis, internalization can proceed via either caveolae-
dependent endocytosis or much less studied mechanisms that do not utilize 
either clathrin or caveolae.  Caveolae-dependent endocytosis is characterized by 
the involvment of the 22-kD membrane-associated protein, caveolin.  Caveolae 
are invaginated plasma membrane domains enriched in cholesterol and 
glycosphingolipids (3-7).   Caveolin binds cholesterol and aids in forming and 
stabilizing the invaginated membrane domains; the loss of caveolin coat allows 
for vesicle formation.  Cells utilize the endomembrane system not only for 
acquiring nutrients from the extracellular environment but also for the packaging 
and shipping of proteins to their destination, namely secretion. 
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The secretory pathway is the export pathway for the cell.  Proteins that are 
synthesized in the endoplasmic reticulum (ER) are packaged for transport to the 
extracellular surface in an anterograde fashion.  A secondary transport pathway 
to maintain membrane homeostasis must offset the secretory pathway.  This 
retrograde pathway is used to recycle proteins and lipids involved in the 
secretory pathway and takes places in three different steps: 1) transport from 
endosomes, early (EE) or late (LE), to the trans-Golgi network (TGN); 2) intra-
Golgi transport; and 3) transport from the Golgi to the ER.   
Transport from the endosomes-to-TGN has been shown to occur by two 
routes.  The first endosome-to-TGN traffic route is the Rab9-dependent pathway 
(8, 9).  This route is characterized by the involvement of the small GTPase Rab9.  
Rab9 organizes the endosome membrane for transport to the TGN.  The second 
endosome-to-TGN transport pathway is thought to function between the recycling 
endosomes, a subclass of the EE, via another small GTPase, Rab11, that 
regulates membrane distribution inside the recycling endosomes (10).   
The intra-Golgi transport pathway is yet unresolved.  Anterograde 
transport within the Golgi complex still needs to be elicudicated.  It is possible 
that transport occurs via vesicular carriers (11).  Another argument is that 
transport occurs via the maturation of Golgi cisternae (12).  Both sides of the 
argument are in agreement, however, that vesicle-mediated retrograde transport 
within Golgi must occur to maintain Golgi homeostasis.  Identification of the 
machinery involved with intra-Golgi retrograde transport is difficult to confirm due 
to the difficulty in interpretation of trafficking data.   
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Retrograde traffic from the Golgi to the ER also utilizes multiple pathways.  
Some proteins contain a KDEL sequence that acts as a retrieval sequence in the 
Golgi (COPI-dependent) (13-15).  Binding of KDEL-tagged proteins to the KDEL 
receptor allows for the binding of the small GTPase Arf1.  Activated Arf1 is 
recruited to the cargo receptor complex.  Arf1 then recruits COPI coat protein 
complex which promotes vesicle formation.  COPI coated vesicles are targeted to 
the ER.  In this manner the KDEL sequence acts as a retention tag for the ER.  A 
number of protein toxins have been shown to contain a KDEL sequence and 
utilize the COPI-dependent pathway (16-18).  There are, however, a subset of 
these protein toxins are still able to traffic to the ER when COPI trafficking is 
disrupted.  Little is known about this COPI-independent pathway (19, 20).  
Proteins that proceed to the ER can exit the endomembrane system. 
Export from the ER to the cytosol can occur through one of two pores 
located on the ER membrane: Sec61 (21-27)and/or Derlin-1 (28).  The Sec61 
protein complex is the main translocon utilized during co-translational 
translocation of proteins into the endomembrane system.  Most of these proteins 
are destined for secretion.  Ribosomes bind the mRNA and translation of the 
proteins begins.  Translation results in an N-terminal signal sequence.  A signal 
recognition protein (SRP) binds to the ribosome and the translated signal 
sequence halting translation of the protein.  The ribosome-SRP complex binds to 
an SRP receptor located on the ER membrane, which transfers the ribosome to 
the Sec61 translocon.  Transfer to the Sec61 translocon allows release of the 
SRP and SRP receptor and protein translation resumes into the ER lumen.  
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Immediately upon entering the ER the newly synthesized protein undergoes a 
number of post-translational modifications.  The signal sequence is cleaved and 
glycosylation occurs to help promote proper folding and assembly.  If the proteins 
are unable to fold properly they are exported back through the Sec61 translocon 
through a process called ER associated degradation (29).  Recent evidence has 
revealed that a second pore is capable of retro-translocation.  Over expression of 
a dominant-negative Derlin-1 inhibited the ER to cytosol transfer of the catalytic 
subunit of cholera toxin (CTA1), suggesting Derlin-1 is responsible for CTA1 
retro-translocation (28). 
 
1.2 ER-Associated Degradation 
 
The ER is the site for folding and packaging of proteins destined for 
secretion or residence within the endomembrane system.  As proteins are co-
translationaly translocated across the ER membrane, several covalent 
modifications take place.  These modifications are a part of the quality control 
system within the ER to ensure proper folding and organelle distribution.  The ER 
also contains numerous molecular chaperones that serve to correct non-native 
conformations.  BiP is a member of the Hsp70 family that recognizes misfolded 
proteins by binding to hydrophobic amino acid sequences that are normally 
buried in properly folded proteins (30).  ER DNA J homologue proteins (ERdj) 
serve to stimulate the function of BiP (31). Protein disulfide isomerase (PDI) 
helps to form disulfide bonds by catalyzing the oxidation and isomerization of 
sulfhydryl groups on cysteines (32).  Calnexin and calreticulin are lectins that 
bind to monoglucosylated N-linked oligosaccharides that occur after removal of 
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glucose residues by ER glucosidases.   ERp57 interacts with the calnexin- or 
calreticulin-bound proteins to generate disulfide bonds (33, 34).  Glucosidase II 
removes the final glucose from the protein.  If the protein is correctly folded, 
glucosyltransferases (GT) will not be able to add glucose sugars to the protein 
and it can be exported from the ER.  In the event that the protein is incompletely 
folded, the GT will add a glucose residue and return the protein to the 
calnexin/calreticulin cycle in an effort to fold the protein properly (35).  In the 
event that the protein cannot attain a native conformation, the proteins are 
selected for retro-translocation to the cytoplasm where they can be degraded by 
the 26S proteasome.  Terminally misfolded proteins are targeted to the Sec61 
and/or Derlin-1 pores by a complex of BiP and at least one HSP40 co-
chaperone, HEDj or ERdj3 (36).  Upon export from the ER lumen, the misfolded 
proteins are ubiquitinated.  The 19S cap of the proteasome recognizes the 
ubiquitinated proteins and further unfolds the proteins for degradation by the 20S 
proteasomal core (37). 
 
1.3 AB Type Protein Toxins 
 
Plants and bacteria utilize a number of protein toxins for cytotoxic or 
cytopathic activity in mammalian cells.  One group of these protein toxins is 
referred to as AB-type protein toxins. This group of toxins includes: cholera toxin 
(CT), Ricin, Shiga toxin, exotoxin A (ETA), pertussis toxin, diphtheria toxin (DT) 
and anthrax toxin.  These toxins are characterized by their catalytic A subunit 
and their cell binding B subunit.  AB-type protein toxins bind to a wide assortment 
of cell receptors and utilize multiple endocytic pathways(38-40).  These toxins 
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attack a wide array of cytosolic targets with various enzymatic activities.  The one 
thing all these toxins have in common is that they all bind to the extracellular 
surface of mammalian cells and must find a way to translocate across a 
membrane to reach their cytosolic targets.  AB protein toxins bind to the cell 
surface and are internalized by varying endocytic mechanisms.  DT and the 
anthrax toxins are able to escape the endosomal compartment by virtue of pH-
induced conformational rearrangement that allows these toxins to create their 
own pore within the endosomal membrane (41, 42).   The other AB toxins listed 
above are trafficked to the ER (42-45).  Upon arrival in the ER, the A subunit 
dissociates, attains a conformation that mimics a misfolded protein, and is 
targeted by ERAD for retro-translocation out of the ER.  As previously mentioned, 
ERAD substrates are ubiquitinated and targeted to the proteasome for 
degradation (46).  Ubiquitination occurs on lysine residues.  AB toxins are 
capable of avoiding proteasomal degradation due to their lysine deficiency in the 
A subunits (47).  Now released from the ER membrane system and unaffected 
by proteasomal degradation, the toxins are free to attack their cytosolic target.
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1.4 Models for Translocation 
 
As previously stated, the problem shared by all AB toxins is the necessity 
for traversing the organelle membrane barrier for intoxication.  DT and anthrax 
toxin are able to escape the endosomal membrane system with pH-induced 
alterations in protein structure that allow the toxins to create their own pore to the 
cytosol.  The other listed toxins are not capable of self-translocation and must 
rely on pores already in existence within the cell.  There is only one location in 
the endomembrane system that contains pores capable of allowing exit for the 
toxins, which is the ER.  The toxins travel in a retrograde fashion to the ER where 
they masquerade as misfolded proteins to utilize the ERAD system for export to 
the cytosol (48, 49).  CT escape from the ER requires: reduction of the disulfide 
bond between the A1 and A2 subunits, disassembly of the holotoxin into CTA1 
and CTA2-CTB, and unfolding of the A1 subunit into a translocation-competent 
state.  Reduction the disulfide bond occurs when the holotoxin arrives in the ER.  
Although the conditions of the ER are normally suited for disulfide bond 
formation, the GSH/GSSG ratio within the ER is capable of reducing the disulfide 
bond that bridges CTA1 and CTA2-CTB (50).  PDI then facilitates the 
disassembly of the reduced holotoxin.   
It has been reported that PDI also plays a role in the active unfolding of 
the CTA1 subunit (51).  The previous model for CT translocation suggests that 
the holotoxin is reduced in the ER, and PDI unfolding of holotoxin-associated 
CTA1 is what dislodges CTA1 from the holotoxin. An alternate model presented 
here suggests that CT is reduced in the ER and that PDI mediates dissociation of 
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the CT subunits.  This model was based solely on an indirect biochemical 
experiment using the cleavage of CTA1 by trypsin (51).  The trypsin cleavage 
assay is an in vitro assay where a protein is treated with trypsin to determine its 
folding state, because unfolded proteins should be cleaved more readily.  By this 
(51) assay PDI was shown to make CTA1 more vulnerable to trypsin.  The 
unfoldase activity of PDI has been largely the subject of debate.  We believe that 
PDI serves only to dislodge the CTA1 from the rest of the toxin and that it does 
not actively unfold CTA1.  In contrast to the original model, we have shown that 
CTA1 is a thermally unstable protein and that dissociation from the rest of the 
holotoxin allows spontaneous unfolding of CTA1 (56‐58).  Here, we will 
demonstrate using direct biophysical measurements that PDI does not unfold 
CTA1; it only removes CTA1 from the A2/B portion of the toxin.  CTA1 is 
thermally instability is responsible solely for its translocation competence and if 
that was stabilized it could halt progression out of ER. 
We predict stabilized CTA1 will not be recognized as a misfolded protein 
by ERAD and will be unable to exit the ER, thus preventing intoxication.  We 
predict that a chemical chaperone 4-phenylbutyrate (PBA) will stabilize CTA1 
within the ER and will block unfolding and translocation into the cytosol.  The 
inability of CTA1 to reach the cytosol will ultimately block intoxication.  Not only 
must the toxin achieve a translocation competent state, but it must also be 
actively extracted from the ER. 
The original model of CTA1 translocation mentioned before stated that 
CTA1 is stable and must be actively unfolded and delivered to Derlin-1 for 
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translocation.  It would refold as soon as it proceeded through the pore, 
extracting itself through what is called the molecular ratchet.  With this model, 
CTA1 will begin to refold as soon as it emerges at the cytosolic face of the ER 
membrane.  The refolding will not allow it to return back into the ER pore.  
Because CTA1 is thermally unstable and unfolds at physiological temperatures 
the molecular ratchet model doesn’t work.  CTA1 must actively be dislocated out 
of the ER into the cytosol.  CTA1 must also refold and maintain a folded 
conformation in order to act on its target.  There must be a cytosolic protein or 
complex that is responsible for the extraction to CTA1 from the ER into the 
cytosol.  Hsp90 is a folding chaperone that has been shown to be associated 
with the cytosolic lumen of the ER.  We show that Hsp90 binds to CTA1 very 
tightly invitro.  We hypothesize that Hsp90 is involved in the extraction of CTA1 
out of the ER into the cytosol.  Blocking the interaction of Hsp90 and CTA1 











CHAPTER 2 MATERIALS AND METHODS 
 
2.1 Chemicals and Reagents 
 
Sigma Aldrich (St. Louis, MO) 
Calcium Chloride (CaCl2) 
Ethylenediaminetetraacetic Acid (EDTA) 
Leupeptin 
N-ethyl maleimidie (NEM) 
Niaproof-4 (NP-40) 
Pepstatin 
Phenymethylsulfonyl Flouride (PMSF) 
Potassium Chloride (KCl) 




Trichloroacetic Acid (TCA) 
 
Fisher Scientific (Pittsburgh, PA) 
2-Mercaptoethanol (β-ME) 
Deoxycholic Acid  
Ethanol 200 proof (EtOH) 
Gel Code Blue Stain Reagent 
Glycerol 
Hydrochloric Acid (HCl) 
Magnesium Cholride (MgCl2)  
Methanol (MeOH)  
Sodium Acetate (NaCH3COO) 
Sodium Chloride (NaCl) 
Sodium Hydroxide (NaOH) 
Sodium Phosphate Dibasic Anhydrous (Na2HPO4) 
Sodium Phosphate Dibasic Heptahydrate (Na2HPO4·7H2O)  
Sodium Phosphate Monobasic Anhydrous (NaH2PO4) 
Sodium Phospate Monobasic Monohydrate (NaH2PO4·H2O)  




Invitrogen (Carlsbad, CA) 
Antibiotic-Antimycotic  
Dulbecco’s Modified Eagle Medium (DMEM) 
Geneticin  






Amresco (Solon, OH) 
Ammonium Persulfate (APS)  




Sodium Dodecyl Sulfate (SDS) 
Tris-Cl  
Triton X-100  
 
Calbiochem (La Jolla, CA) 
Adenodine Triphosphate (ATP) 
Digitonin 
 
Bio Rad (Hercules, CA) 
40% Acrylamide /Bis Solution 
Extra Thick Filter Paper  
 
BostonBiochem (Cambridge, MA) 
20S Proteasome 
 
Beckman Coulter (Fullerton, CA) 
Scintillation Fluid  
 
Perkin Elmer (Waltham, MA) 
[35S] Methionine  
 
Alpha Biosciences (Baltimore, MD) 
Yeast Extract  
 
Atlanta Biologicals (Lawrenceville, GA) 
Fetal Bovine Serum  
 
Millipore (Billerica, MA) 
Immobilin (PVDF)  
 
BD Biosciences (San Jose, CA) 
Skim Milk  
 
GE Healthcare (Piscataway, NJ) 









List Biological Laboratories (Campbell, CA) 
Cholera Toxin, Holotoxin 
 
Calbiochem (La Jolla, CA) 








Sigma Aldrich (St. Louis, MO) 
Rabbit α-CTA  
 
Jackson Immunoresearch (West Grove, PA) 




Bio Rad (Hercules, CA) 
Bio Rad Power Pac Basic  
Bio Rad Power Pac HC  
Model 853 Gel Dryer  
Trans-Blot SD Semi-Dry Transfer Cell  
 
Beckman Coulter (Fullerton, CA) 






GE Healthcare (Piscataway, MJ) 
Äkta purifier 




BioTek Instruments (Winooski, VT) 
Synergy 2 Plate Reader  
 
Jasco (Tokyo, Japan) 
4200 FTIR Spectrometer 
2.5 Other Materials 
 
Grenier Bio One 
6-well flat-bottom tissue culture plates 
24-well flat-bottom tissue culture plates 
96-well black, flat-bottom tissue culture plates 
 
GE Healthcare (Piscataway, MI) 
GSTrap HP (GST glutathione column) 
 
American Type Culture Collection 




Invitrogen (Carlsbade, CA) 
d2eGFP plasmid 




Phosphate Buffered Saline (PBS), 10x 
 82.3 g Na2HPO4 (0.58M) 
 23.5 g NaH2PO4 (0.17M) 
 40 g NaCl (0.69M) 
 H2O to 1 liter 
 
Tris-Buffered Saline (TBS), 10x 
 24.24 g Tris-Cl  
 5.56 g Tris Base 
 80.1 g NaCl 
 H2O to 1 liter 
 
Transfer Buffer 
 100 ml 10x SDS-Electrophoresis Running Buffer 
 200 ml MeOH 
 600 ml H2O 
 
SDS-Electrophoresis Running Buffer, 10x 
 30.2 g Tris Base 
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 144 g Glycine 
 10 g SDS 
 H2O to 1 liter 
 
SDS sample buffer, 4x 
 50 ml 4x Tris-Cl/SDS pH 6.8 
 40 ml Glycerol 
 8 g SDS 
 2 mg bromophenol blue 
 100 mM 2-mercaptoethanol (7µl of 14.3 M ß-ME /ml of 4x buffer) 
 
Lysis Buffer 
 25 mM Tris-Cl pH 7.4 
 20 mM NaCl 
 1% Deoxycholic Acid 
 1% Triton X-100 
 1 mM Phenylmethylsulfonyl fluoride (PMSF) 
 1 µg/ml Pepstatin 
 1 µg/ml Leupeptin 
 
NDET 
 1% NP-40 
 0.4% Deoxycholic Acid 
 5 mM EDTA 
 10 mM Tris-Cl, pH 7.4 
 150 mM NaCl 
 
Sodium Phosphate Buffer, 0.1 M 
 Solution A: 27.6 g NaH2PO4·H2O per liter (0.2 M) 
 Solution B: 53.65 g Na2HPO4·7H2O per liter (0.2 M) 
 
 100 ml of pH 7.0 buffer add 39.0 ml of solution A and 61 ml of solution B 
  
HCN Buffer 
 50 mM HEPES, pH 7.5 
 150 mM NaCl 
 2 mM CaCl2 
 10 mM N-ethyl maleimide (NEM) 
 1:20 dilution of Protease Inhibitor Cocktail 
 
20S Proteasome Assay Buffer, 2x 
 100 mM HEPES, pH 7.5 
 20 mM MgCl2 
 200 mM KCl 
 0.2 mM CaCl2 
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GST Protein Purification Buffer 
 100 mM KCl 
 20 mM Tris-Cl, pH 7.5 




 10g Tryptone 
 5 g Yeast Extract 
 5 g NaCl 
 H20 to a liter 
 
2.7 Tissue Culture 
 
Cells seeded to a 10 cm dish were washed once with Phosphate Buffered 
Saline (PBS).  1 ml of trypsin-EDTA was added to the plate and incubated at 
37°C for 5 minutes.  9 mls of the appropriate complete tissue culture media 
(containing 10% fetal bovine serum (FBS) (Atlanta Biological Lawrenceville, Ga.) 
and 1% antibiotic-antimycotic (Invitrogen Carisbad, CA.)) was added to the plate 
and titurated to resuspend the cells.  CHO cells require Ham’s F-12 (Invitrogen); 
and HeLa require Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen). 9 mls 
of complete media was added to a new 10 cm dish and 1 ml of the cell 
resuspension was added to the new 10 cm dish.  The seeded dish was rocked 
back and forth to ensure even distribution of the cells on the plate.  When the 
cells reached 80% confluency on the 10 cm dish, they were again split. 
Variations of the above protocol were used for alternate incubation times 
and for seeding to alternate plates.  The dilution of 1 ml cell resuspension to 9 ml 
complete media reached 80% confluency after 3-4 days of incubation at 37°C.  A 
dilution containing 0.5 ml of cellular resuspension and 9.5 ml of media was often 
used to extend the incubation of cells to 4 days.  For incubation times greater 
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than three days, the media was removed and replaced with 10 ml of fresh media.  
Cells that were seeded into a 6-well plate required a dilution of 1 ml cellular 
resuspension to be added to the well along with an additional 0.5 ml of media.  
Cells seeded into 6-well plates at this dilution reached 80% confluency in 18-24 
hours.  Cells that were seeded to 24-well plates required a dilution of 1 ml of 
cellular resuspension to be mixed with 5 ml of complete media.  0.5 ml of the 





CHO cells were seeded to a 6-well plate and grown to 80% confluency 
following an overnight incubation at 37°C.  Following the incubation transfection 
mixtures were prepared in eppendorf tubes.  Solution A was placed in one tube 
consisting of 1 µg of DNA per 100 µl of serum-free media.  Solution B was placed 
in a separate tube consisting of 5 µl of Invitrogen lipofectamine reagent per 100 
µl of serum-free media.  Solution A and solution B were then combined and 
incubated at room temperature for 30 minutes.  The cells were washed with 2 ml 
of serum-free media to remove any residual media the cells were seeded in.  
One ml of serum-free media was added to each well followed by 200 µl of the 
DNA/lipofectamine transfection mixture.  Following a 3 hour incubation at 37°C, 
the transfection mixture was removed, the cells were washed with antibiotic- and 
serum-free media, and 1.5 ml of serum-free media was added for overnight 
incubation at 37°C.  Co-transfection assays in CHO cells consisted of 1 µg of 
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DNA for each plasmid per 100 µl of serum-free media.  Solution B remained the 
same.  
For transfection of HeLa cells solution A consisted of 0.5 µg DNA per 100 µl 
of serum-free media, and solution B consisted of 8 µl of lipofectamine per 100 µl 
of serum-free media.  HeLa cells were incubated with transfection mixture for 5 
hours at 37°C.  All other steps were identical to the above protocol for 
transfection of CHO cells. 
 
 
2.9 Toxicity Assay – cAMP 
 
Cells were seeded into flat-bottom 24 well plates and grown overnight to 
80% confluency (in triplicate).  The media was removed and replaced with 
serum-free media containing the various concentrations of CT in the absence or 
presence of drug treatments.  After a 2 hour incubation the cells were washed 
with PBS, and 0.25 ml of ice cold HCl:EtOH (1:100) was added for 10 minutes at 
4°C or on ice.  The liquid was removed, placed in microcentrifuge tubes and 
allowed to air dry.  cAMP levels were then determined using a (Perkin Elmer 
Waltham, MA) [125I] cAMP competition assay kit as per the manufacturer’s 
instructions.  The values obtained were then background subtracted from cells 
that were treated with no toxin.  The maximum response was arbitrarily set to 





2.10 Translocation Assay 
 
HeLa cells were seeded to 6-well plates in complete DMEM media to 
achieve 10,000 cells/well after an overnight incubation at 37°C.  Triplicate wells 
were required for each condition.  Following the overnight incubation, the media 
was replaced with serum-free, antibiotic-antimycotic free DMEM (DMEM Only) 
media containing 100 ng/ml of GM1 and incubated at 37°C.  After a 1 hour 
incubation, the media was replaced with 1 ml of DMEM only containing 1 µg/ml of 
CT and placed at 4°C.  After a 30 minute incubation, the media was removed and 
the cells were washed with PBS prior to being lifted from the 6-well plate using 
750 µl of 0.5 mM EDTA in PBS per well.  Three wells for each condition were 
added to a single microcentrifuge tube and spun at 5,000 x g for 5 minutes.  The 
supernatant was discarded and the pellet was resuspended in 0.04% Digitonin in 
HCN buffer and placed on ice for 10 minutes.  The samples were spun at 16,000 
x g for 10 minutes, and the supernatant was collected and placed in a fresh 
microcentrifuge tube.  Samples to be analyzed by Western blot analysis received 
120 µl of 1x sample buffer to the pellet fraction and 20 µl of 4x sample buffer to 
the supernatant fraction.  The samples were run on 15% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) gels for electrophoresis.  
Samples to be analyzed by surface plasmon resonance (SPR) received HCN 
buffer to 1 ml.  Samples for the co-transfection translocation assays were 
resuspended to a volume of 1 ml in lysis buffer after the final centrifugation step.  
These samples were pre-cleared with protein A sepharose beads.  Following an 
overnight incubation at 4°C, the samples were spun at 5,000 x g for 5 minutes.  
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2.11 Western Blot Analysis 
 
Twenty five microliters of sample were loaded to a 15% SDS-PAGE gel.  
The samples were allowed to run at 200 Volts for 60 minutes.  Gels were washed 
2 times in water and then equilibrated in transfer buffer for 10 minutes along with 
2 pieces of filter paper.  PVDF membrane was placed in MeOH for 10 seconds 
and then transfer buffer for 10 seconds for activation.  One piece of filter paper 
was placed on the bottom platinum anode of the BioRad transfer apparatus 
followed by the activated membrane then the equilibrated gel and the second 
piece of filter paper.  Air bubbles were rolled out prior to securing the top cathode 
and safety cover.  The transfer was conducted for 20 minutes at 10 Volts and 
then 40 minutes at 15 Volts.  The membrane was then incubated overnight at 
4°C in 1% milk in TBS-T with primary antibody (rabbit α-HSP90 1:20,000; rabbit 
α-PDI 1:5,000; rabbit α-CTA 1:20,000).  After incubation the membrane was 
washed in 1% milk in TBS-T for 5 minutes.  The membrane was then incubated 
at RT for 30 minutes with secondary antibody (rabbit IgG conjugated Horseradish 
Peroxidase 1:20,000).  Following incubation the membrane was washed once in 
1% milk for 5 minutes and once in TBS-T for 5 minutes.  ECL Plus Western 
blotting detection reagents were used for detection following manufacturers 






Cells were seeded to 6-well plates and transfected as previously 
described in triplicate.  Cells were transfected with an empty vector (pcDNA 3.1), 
mCTA1 plasmid or ssCTA1 plasmid (52).  Following an overnight post-
transfection incubation, the cells were incubated for 1 hour at 37°C in 0.5 ml of 
methionine-free media.  The cells were then washed with PBS and incubated for 
1 hour at 37°C in 0.5 ml of methionine-free media containing 75 μCi [35S] 
methionine.  The cells were washed with PBS and lifted from the wells with 750 
μl of 0.5 mM EDTA in PBS and placed into separate microcentrifuge tubes.  The 
tubes were centrifuged at 5,000 x g for 5 minutes.  The supernatant was 
discarded and the cell pellet was resuspended in 100 μl of 0.04% digitonin in 
HCN buffer and placed on ice for 10 minutes.  The samples were then spun at 
16,000 x g for 10 minutes and the supernatant (i.e. cytosolic fraction) was 
collected and placed into a separate microcentrifuge tube.   1 ml of lysis buffer 
was added to the pellet (i.e. membrane fraction) and 900 μl of lysis buffer was 
added to the supernatant fraction.  Following incubation at 4°C for 20 minutes, 3 
μl of anti-CTA antibody was added to each 1 ml fraction and incubated on a 
rocker at 4°C.  Following an overnight incubation, 30 μl of a protein A slurry 
prepared by the manufacturer’s protocol was added to each fraction and 
incubated on a rocker at 4°C.  Following a 2 hour incubation, the samples were 
centrifuged for 5 minutes at 5,000 x g.  The pelleted beads were washed 2 times 
with 1 ml NDET and once with 1 ml of water.  50 μl of 1X sample buffer was 
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added to each pellet.  The samples were run on a 15% SDS-PAGE gel and dried 
to filter paper using a Bio Rad (Hercules, CA) gel dryer.  The dried gels were 
placed in a PhosphoImager cassette for 4 days and analyzed using a Storm 840 
Phospho-Imager and Image Quant software (Sunnyvale, CA.).  Background was 
subtracted from all samples prior to data calculations.  Percentage of cytosolic 
CTA1 was defined as the supernatant divided by pellet plus supernatant (% 
ytosol = sup/[pellet+sup]). c
 
 
2.13 SPR Sensor Slide Generation 
 
Gold-plated glass slides with a self-assembled monolayer, purchased from 
Reichert (Depew, NJ), were activated by perfusing an EDC-NHS activation buffer 
for 10 minutes.  The activated plate was then washed for 5 minutes with PBS 
(pH7.4) containing 1% Triton X-100 (PBST).  Antibody was perfused over the 
activated sensor slide at a dilution of 1:2,000 in PBST for 15 minutes.  Unbound 
antibody was washed off the sensor slide with a 5 minute PBST wash.  
Ethanolamine was perfused over the sensor slide for 3 minutes to cap any 
unbound tethers on the gold plated plate.  All perfusions were at a flow rate of 5 
μl/min 
 
2.14 SPR Analysis 
 
PBST was perfused over the antibody bound sensor slide for 5 minutes to 
establish a baseline reading.  Experimental samples were perfused over the anti-
body bound sensor slide.  Following each experimental condition, bound ligand 
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was removed from the sensor slide by washing the slide with PBST at pH 6.0.  
Reichert Labview software was used for data collection.   
The cytosolic pools generated were diluted in HCN buffer to a volume of 1 
ml.  For the translocation assays, the 100 μl sample generated from the digitonin 
permeabilization was too small to run through the SPR instrument.  CTA1 
standards were diluted in HCN buffer for the translocation assay.  Secretion 
assays required all samples to be standardized to contain 5% glycerol in order to 
eliminate any effects that glycerol might have on the detection by the SPR 
instrument. CTA1 standards were therefore diluted in 5% glycerol for the 
secretion assays.  All solutions were perfused over the sensor slide at a flow rate 
of 5 μl/min. 
 
2.15 SPR Holotoxin Slide Generation 
 
Gold sensor slides were purchased from Reichert.  These sensor slides were 
treated with a GM1 solution at a concentration of 1 mg/ml.  This solution was 
allowed to air dry at room temperature.   CT was added in a PBS solution at 
1ug/ml for 1 hour.  The plate was then blocked with BSA at a 20 ug/ml 
concentration for 1 hour. 
 
2.16 SPR Holotoxin /PDI Dissociation 
Plates were equilibrated with PBS-T at pH 7.4 for 5 to 10 minutes.   Reduced PDI 
was then injected at a concentration of 1 ug/ml.  After a loss of mass was 
recorded and a new base line has been recorded, a monoclonal antibody against 
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CTA1 was added at 1:500 dilution in PBS-T.  A PDI antibody followed the CTA1 
antibody at a dilution of 1:10000.  The next antibody that was flowed over the 
slide was either a KDEL antibody at 1:10000 or a CTB antibody at 1:15000.  
 
2.17 Fourier Transform Infrared Spectroscopy 
Protein samples were prepared in D2O buffer containing 10 mM sodium borate 
(pH 6.6).  The samples contained either unlabelled PDI or 13C- labelled CTA1 or 
both in a 1:1 molar ratio.  FTIR experiments were carried out on a Jasco 4200 
FTIR scectrometer at 0.964 cm-1 spectral resolution.  The absorbance was 
calculated using the respective buffers as a refrence and corrected by the 
subtraction of H20 vapor contribution.  Curve fitting was evaluated in the amide 1 





















It was accepted that only the reduced form of PDi would interact with the A 
subunit of cholera toxin (53, 54).  Reduced PDI was originally proposed to unfold 
CTA1 subunit while it wa in association with the holotoxin.  This unfolding is what 
thereby promote the separation of CTA1 from the rest of the holotoxin (51).  PDI 
was also linked to the delivery of CTA1 to the translocon pore Derlin-1 (28, 55).  
CTA1 was released to the Derlin-1 throught the oxidation of PDI by Ero1p (56).  It 
is in this manner that it was stated that PDI is a redox-dependant unfoldase of 
CTA1.  
3.2 CTA1 does not require PDI in order to become translocation competent 
 
Recent structural studies, done by the Teter Lab, have indicated that CTA1 
will unfold spontaneously after dissociation from the holotoxin at physiological 
temperature (57-59).  With this information It is no longer necessary for PDI to 
actively unfold CTA1 and therefore unlikely.  It is more likely that PDI has a more 
inimal role in intoxication.   m
 
3.3 PDI interacts with CTA1  
 
According to the original model of translocation, PDI must bind tightly to 
CTA1 in order to unfold and then deliver CTA1 to the translocon.  Direct binding 
studies using SPR indicate that PDI does bind to CTA1 directly (Fig 3-1).  
  25
Binding studies were carried out under conditions that mimic CTA1 structure in 
association with the holotoxin.  It is expected that PDI will interact with CTA1 in 
the holotoxin.  Two conditions that are known to stabilize CTA1 as it it is 
stabilized in association with the holotoxin are acidic pH and 10% glycerol (56-
58).  PDI binds CTA1 under stabilizing conditions but not under physiological 
conditions.  Unlike the previous model where PDI would delivers an unfolded 
CTA1 to the translocon, PDI could not bind an unfolded CTA1 (Fig. 3-1).  PDI 
readily binds the folded conformation of CTA1, but can no longer bind with a loss 
of CTA1 structure.   Because CTA1 will unfold after separation from CTA2/CTB5, 
and because PDI cannot remain bound to unfolded CTA1 it is unlikely that PDI is 
responsible for delivery of CTA1 to the translocon. 
PDI will interact with CTA1 in the holotoxin when PDI is in the reduced state 
(Fig. 3-2).  The idea that CTA1 is stabilized in association with the holotoxin has 
been well established (44-45) and is likely the reason for the misconception that 
CTA1 is stable at physiological temperatures.  PDI will bind only to the A subunit 
of the holotoxin and then only to its folded conformation (Fig. 3-2).  When 
reduced PDI binds to CTA1 in the holotoxin robust binding occurs followed by a 
distinct drop in signal by SPR.  This loss of signal represents a shift in refracted 
light that reflects a loss of mass from the sensor slide.  The amount of mass lost 
from the sensor slide represents much more mass than the amount of PDI that 
was bound to the slide (Fig. 3-2).  The loss of mass also may be coming from the 
sensor slide itself.  Antibody controls of CTA1, CTB, and KDEL distinctly show 
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that the A1 subunit of CT is being removed by the interaction of reduced PDI and 
CTA1.   
The holotoxin plates are bound to the SPR plate by GM1.  CTA1 antibody 
shows that CTA1 is no longer present on the plate after exposure to reduced 
PDI, while CTB and KDEL antibodies show that the B-pentamer and A2 linker 
are both still present on the sensor slide (Fig. 3-2b).  The PDI antibody shows 
that PDI is also being lost from the plate, indicating that PDI is binding to CTA1  
(Fig 3-2b).  Stabilization of CTA1 using low pH or low temperature did not block 
the activity of PDI in dissociation of CTA1 (Fig. 3-3).  The previous model that 
required PDI unfolding of CTA1 in order to dissociate it from the holotoxin, are 
shown to be inaccurate in this figure.  CTA1 can be stable and still be dissociated 
from the holotoxin.  Another part of that model stated that PDI delivers CTA1 to 
the translocon.  To address this, a SPR plate was created with CT holotoxin 
bound by an antibody against the A subunit.  When this antibody-bound holotoxin 
plate was treated with reduced PDI, dissociation occurred as before (Fig. 3-4).  In 
this case when dissociation occurs the CTA1 subunit is left on the plate.  If PDI 
remains with the freed CTA1subunit in order to deliver it to the translocon, then 
PDI should stay bound to CTA1 on the SPR plate.  This was not the case.  The 
antibody controls show that PDI is no longer on the plate after holotoxin 







Figure 3-1 Binding of reduced PDI to CTA1 
 
CTA1 unfolding displaces toxin-bound PDI.  (A-B)  Reduced PDI (PDI + 1 mM 
GSH) was perfused over a CTA1-coated sensor slide at 37°C in pH 6.5 buffer.  
After 250 sec, the pH of the perfusion buffer was either (A) maintained at pH 6.5 
or (B) shifted to pH 7.0.  PDI was present in the perfusion buffer throughout the 
experiment.  (C-D)  Reduced PDI (PDI + 1 mM GSH) was perfused over a CTA1-
coated sensor slide at 37°C in buffer containing 10% glycerol.  After 250 sec, 
glycerol was either (C) maintained or (D) removed from the perfusion buffer.  PDI 





Figure 3-2 CTA1 dislocation assay  
Dissociation of the CT holotoxin by reduced PDI.  (A) The following ligands were 
perfused over a CT-coated SPR sensor slide at 37°C:  PDI, oxidized PDI (PDI + 
1 mM GSSG), an anti-CTA antibody, an anti-CTB antibody, and an anti-KDEL 
antibody.  (B) After taking a baseline measurement corresponding to the mass of 
the sensor-bound holotoxin, reduced PDI (PDI + 1 mM GSH) was perfused over 
the CT-coated sensor slide at 37°C.  PDI was removed 400 sec into the 
experiment and replaced with sequential additions of anti-PDI, anti-CTA, and 






Figure 3-3 CT disassembly under conditions that prevent the unfolding of 
CTA1 
 After appending CT to a GM1-coated sensor slide, a baseline measurement 
corresponding to the mass of the bound holotoxin was recorded.  Reduced PDI 
(PDI + 1 mM GSH) was then perfused over the CT-coated sensor at either (A) 
37°C in pH 6.5 buffer or (B) 10°C in pH 7.0 buffer.  PDI was removed 400 sec 
into the experiment and replaced with sequential additions of anti-PDI, anti-CTA, 
and anti-KDEL antibodies as indicated by the arrowheads.  In panel A, an anti-







Figure 3-4 CTA1 Association of PDI with CTA1 after holotoxin disassembly 
 CT was appended to a SPR sensor slide coated with a polyclonal anti-CTA 
antibody, and a baseline measurement corresponding to the mass of the bound 
holotoxin was recorded.  Reduced PDI (PDI + 1 mM GSH) was then perfused 
over the CT-coated sensor at 37°C.  PDI was removed from the perfusion buffer 
400 sec into the experiment and replaced with sequential additions of an anti-PDI 
antibody, an anti-CTB antibody, an anti-KDEL antibody, and an anti-CTA 
monoclonal antibody as indicated by the arrowheads.  An identical result was 
obtained when CT was initially appended to a sensor slide coated with the 







3.4 Effect of PDI on CT Toxicity 
 
If CTA1 unfolds by itself, then what role if any is PDI playing in intoxication?  
PDI has been shown to remove the A1 subunit from the holotoxin in the previous 
experiments.  PDI is also linked to the toxicity of CT.  To address the link of PDI 
to the toxicity of cholera toxin, we utilized PDI deficient cells (Fig. 3-5).  The PDI 
deficient cell lines stably produce small interfering siRNA that repress the 
production of PDI.  The PDI deficient cell lines are resistant to exogenously 
applied CT (Fig. 3-5a).  PDI deficient cell lines were not resistant to CTA1 that 
was transfected directly into the ER (Fig. 3-5b).  This result points out that when 
CTA1 that is free in the ER has no need to interact with PDI.  In contrast, CTA1 
in the holotoxin requires PDI to remove it from the holotoxin within the ER.  This 
evidence along with the SPR data points to a more limited role of PDI in cholera 
intoxication than previously suggested.  The role of PDI in intoxication may now 













Figure 3-5 In vivo role of PDI in CT intoxication and CTA1 translocation 
  (A) Parental TZM cells, TZM 1-2 cells stably transfected with PDI siRNA, and 
TZM 5-1 cells stably transfected with a non-specific control siRNA were exposed 
to the stated concentrations of CT for 2 h.  Toxicity was then assessed from the 
rise in intracellular cAMP.  The averages ± standard deviations of three 
independent experiments with triplicate samples are shown.  (B) TZM, TZM 1-2, 
and TZM 5-1 cells were transfected with a plasmid encoding a CTA1 subunit 
appended with an ER-targeting sequence.  cAMP levels recorded at 3 h post-
transfection were standardized to CTA1 expression levels, and the resulting data 
were plotted as percentages of the control response from parental TZM cells.  
The averages ± ranges of 2 independent experiments are shown.  (C) TZM, TZM 
1-2, and TZM 5-1 cells were transfected with a plasmid encoding a CTA1 subunit 
appended with an ER-targeting sequence.  CTA1 immunoprecipitated from the 
membrane (P; pellet) and cytosolic (S; supernatant) fractions of metabolically 
labeled cells were resolved by SDS-PAGE.  The averages ± ranges of cytosolic 
CTA1 calculated from 2 independent experiments are shown in the graph.     
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3.5 Effect of reduced PDI on the folding state of CTA1 
 
The claim of PDI being a CTA1 unfoldase is not only entrenched and 
regularly cited, but was based on an indirect measure of the CTA1 folding state.  
This indirect measure of folding state is a protease assay, which assumes that 
the protease trypsin will cleave an unfolded protein more readily than a folded 
protein.  This assay was not performed at physiological temperature and does 
not accurately represent the folding state of CTA1.   
Direct measurements of folding were required to determine the folding state 
of CTA1 in the presence of reduced PDI.  Fourier transform infrared 
spectroscopy (FTIR) was utilized for this end.  Over a range of temperatures and 
conditions reduced PDI was added specifically to identify any alteration to the 
structure of CTA1 (Fig. 3-6, 3-7).   The percentages of structure that were 
collected from the FTIR experiments are presented in (Table 3-1). 
CTA1 was labelled with 13C in order to shift its spectra 50 cm-1.  This shift 
was necessary so that the amide I region of CTA1 would not overlap with the 
same region of PDI.  With this tool it was possible to distinguish the structure of 
CTA1 from the structure of PDI.  The resulting data demonstrated that CTA1 
does not lose its structure in the presence of reduced PDI.  Compared to the loss 
of structure with temperature alone, PDI does not cause the loss of CTA1 







Figure 3-6 Effect of reduced PDI on the folding state of CTA1  
FTIR spectra were recorded for PDI (dashed line), 13C-labeled CTA1 (dotted 
line), or a 1:1 molar ratio of PDI + 13C-labeled CTA1 (solid line).  All 













Figure 3-7 The 10°C structure of CTA1 in the absence or presence of PDI 
  Curve-fitting (A, C) and inverted second derivatives (B, D) for the FTIR 
spectrum of 13C-labeled CTA1 recorded in the absence (A, B) or presence (C, D) 
of PDI are shown.  In panels A and C, the dotted line represents the sum of all 
deconvoluted components (solid lines) from the measured spectrum (dashed 
line).   
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           % of CTA1 Structure     
Condition α-helix β-sheet irregular other 
10°C 37 48 7 7 
10°C + PDI 36 48 8 9 
30°C  28 36 25 11 
30°C + PDI 27 35 27 11 
37°C pH 6.5 23 32 34 11 
37°C pH 6.5 + 
PDI 
28 29 36 8 
37°C  21 13 51 16 
      
TABLE 3-1 Calculations of cytosolic CTA1 
From the deconvolution of the spectra of the FTIR experiments we compiled a 
table that gives the percentage of CTA1 structure in the presence and absence 










The role of PDI intoxication is limited to the dissociation of CTA1 while the 
unfolding of the CTA1 subunit is spontaneous.  The previous model of PDI-CT 
interactions is based upon the results of a protease sensitivity assay.   This 
assay, which was thought to show that CTA1 shifts from a folded to an unfolded 
conformation, in the presence of reduced PDI actually shows  a difference in free 
CTA1 and CTA1 in the holotoxin.    Direct biophysical analysis of the 
conformation of CTA1 in the presence or absence of reduced PDI did not support 
the interpretation of this indirect experiment.  Our SPR and FTIR data collectively 
demonstrate that PDI removes CTA1 from the rest of the holotoxin where CTA1 
will then spontaneously unfold and displace PDI.  Cell-based studies were used 
to further evaluate the role of PDI in CT intoxication and CTA1 translocation.  
These assays show that PDI is necessary for the intoxication with exogenously 
added toxin.  However, PDI is not needed for toxicity in cells expressing CTA1 in 
the ER as seen in the PDI-deficient cell lines.   
Direct evidence was needed to determine if PDI could act as an unfoldase.  
To this end, FTIR was utilized to determine the folding state of PDI in the 
presence and absence of reduced PDI.  This is the first time a direct, biophysical 
technique has been used to examine the interaction between PDI and CTA1.  
FTIR analyses demonstrate that PDI does not act as an unfoldase.  CTA1 
structure in the presence of PDI is as stable if not more stable than alone.  The 
unfolding of CTA1 is solely due to its spontaneous unfolding at physiological 
temperature. 
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CHAPTER 4  STABILIZATION OF CTA1 BLOCKS 
TRANSLOCATION AND INTOXICATION 
4.1 Introduction 
 
CT binds to the cell surface receptor GM1, is endocytosed and trafficked to 
the ER by retrograde vesicular transport (43, 60-62).  In the ER, the holotoxin 
dissociates into individual A and B subunits (50, 51, 63).  The catalytic CTA1 
subunit mimics a misfolded protein and is recognized by the ER quality control 
mechanism, ERAD, and exported from the ER to the cytosol (64-67).  The 
molecular mechanisms of this export process are poorly characterized.  The 
current model for CTA1 translocation is that upon entry into the ER, PDI binds to 
CTA1 and actively unfolds the toxin (51).  In contrast, we conclude from our data 
that the trigger for the CTA1 translocation event is a thermal denaturation that 
occurs after CTA1 dissociates from the rest of the holotoxin.  Previous work has 
already demonstrated the temperature-dependent conformational instability of 
the CTA1 subunit (58). According to our model, stabilization of the CTA1 subunit 
will prevent translocation and subsequent intoxication.  PBA is chemical 
chaperone that stabilizes protein structure.  Previous reports have indicated that 
glycerol can provide resistance to CT (57).  Glycerol, however, is a poor 
candidate for a preventative or treatment for cholera intoxication because it is 
very toxic itself to cells.   Here we show that PBA prevents the temperature-
dependent loss of CTA1 structure which blocks translocation and results in 
resistance to intoxication.  PBA is a FDA-approved ammonia scavenger, which is 
used to treat urea cycle disorders.  PBA is a prime candidate for a preventative 
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or treatment for CT intoxication, because it is easily tolerated in children and 
adults for oral ingestion.   
4.2 Effect of PBA on CTA1 Translocation 
 
Dr. Tuhina Banerjee of the Teter lab confirmed by circular dichroism that 
100 uM PBA stabilizes CTA1 and prevents it from unfolding at 37°C.  Our model 
suggests that stabilization of CTA1 structure traps the protein in a conformation 
not suitable for translocation.  To test this model, we used a translocation assay 
to monitor the distribution of CTA1 in the cytosol and ER of untreated or PBA-
treated cells.  HeLa cells were incubated on ice for 30 minutes in the presence of 
1 μg/ml of CT.  Cells were pulse-labeled with CT at 4°C, a temperature that 
prohibits endocytosis.   Unbound toxin was removed, and the cells were allowed 
to incubate at 37°C for 2 hours in either in the presence or absence of PBA.  
Digitonin was then used to selectively permeabilize the cells and separate the 
cytosolic fraction from the membrane/organelle fraction.  We selectively 
permeablized control cells to ensure that we could detect PDI, an ER chaperone, 
only in the membrane/organelle fraction.  We also probed for Hsp 90, a cytosolic 
protein that should only be found in the cytosolic fraction.  The selective 
permeabilization of control cells showed that PDI was localized only in the 
membrane/organelle fraction and that Hsp 90 was localized only to the cytosolic 
fraction (figure 4-1a).  These controls confirmed that selective permeabilization 
via digitonin can distinguish cytosolic proteins from membrane/organelle proteins.  
There is a decrease in the cytosolic amount of CTA1 was detected in cells that 
were incubated at 37°C for 2 hours in the presence of PBA then cells were 
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incubated in the absence of PBA (figure 4-1b).  These data demonstrating that 
intoxication in the presence of PBA inhibited CTA1 translocation into the cytosol.  
Western blot analysis revealed that CTA1 was reduced even in the presence and 
absence of PBA demonstrates that CTA1 is being trafficked to the ER properly 
(Fig. 4-2).  Because the disulfide linkage of CTA can only be reduced in the 
environment of the ER, this experiment demonstrating that PBA is not acting on 
any step of toxicity before the ER (42-45).  In order to address the separation of 
CTA1 from the holotoxin we utilized the SPR based PDI dissociation assay in the 
presence of PBA.  Our results demonstrated that PBA does not block the activity 
of PDI in dislodging CTA1 from the rest of the holotoxin (Fig. 4-3).  Thus, the low 
levels of CTA1 in PBA-treated cell did not result from a block of CT transport to 
the ER or a block of holotoxin disassembly. 
 To address the question of how PBA is affecting the translocation of CTA1 
out of the ER, we transfected cells with a construct of CTA1 that is expressed 
directly in the ER and determined the progression of this construct out of the ER 
is not deterred with the addition of PBA (Fig. 4-4).  Because the CTA1 present in 
this assay is being produced directly in the ER all trafficking up to this point is not 
a contribution.  Utilizing pulse labeling with 35S and a selective permeabilization 
assay, following a two hour chase, with PBA present allows us to demonstrate 
that PBA does not affect the translocation of unfolded PBA.  There must be a 
difference in the exogenously added toxin and the transfected toxin in the ER 
that allows for this discrepancy.   Dr. Banerjee from the Teter lab has determined 
by CD that PBA cannot refold CTA1, but can stabilize the toxin in its folded 
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conformation.  It is likely then that PBA stabilizes CTA1 while still in association 
with the holotoxin and never allows it to lose the amount of structure, needed to 
be recognized as an ERAD substrate.  In contrast, PBA cannot stabilize the 
transfected toxin, which enters the ER co-translationally in an unfolded state. 
This experiment demonstrated that PBA does not directly inhibit translocation 
into the cytosol.  With the determination of CTA1 being kept in its folded 
conformation in the presence of PBA, how is the toxicity of CTA1 being affected?  
As expected, CTA1 loses its toxicity without progression out of the ER to reach 
its target  (Fig. 4-5).  PBA has been shown in this study to stabilize CTA1.  















Figure 4-1 SPR analysis of PBA inhibiting CTA1 translocation 
    PBA blocks the translocation of CTA1 into the cytosol.  HeLa cells were 
pulse-labeled at 4°C for 30 min with 1 mg / ml of CT.  The cells were then chased 
for 2 hr at 37°C in toxin-free medium that contained no additions, 100 mM PBA, 
or 5 mg / ml of BFA.  Selective permeabilization of the plasma membrane with 
digitonin was used to partition cell extracts into separate membrane (pellet; P) 
and cytosolic (supernatant; S) fractions.  (A):  Both fractions were probed by 
Western blot to establish the distributions of cytosolic marker Hsp90 and ER 
marker PDI.  (B):  An SPR sensor slide coated with an anti-CTA antibody was 
used to detect the cytosolic pool of CTA1 from untreated (no treatment) or drug-
treated cells.  CTA standards (100, 10, 1, and 0.1 ng / ml) were perfused over the 
sensor slide as positive controls; only the 1 and 0.1 ng / ml standards are shown 
for scaling purposes.  A cytosolic fraction from unintoxicated cells was also 
generated for this experiment.  One of three representative experiments is 





Figure 4-2 Effect of PBA on CT Transport to the ER 
PBA does not prevent the reductive separation of CTA1 from CTA2.  1 mg 
samples of the CTA1/CTA2 heterodimer were exposed to 10 mM β-ME for 5 min 
in the absence or presence of 100 mM PBA before loading on a non-reducing 
SDS-PAGE gel.  1 mg of a CTA1/CTA2 heterodimer that was not exposed to β-
ME was also run on the gel.  Samples were visualized by Coomassie staining, 







Figure 4-3 Effect of PBA on dissembly of the CT holotoxin 
PBA does not block the dissociation of CTA1 from CTA2/CTB5.  After appending 
CT to a GM1-coated SPR sensor slide, a baseline measurement corresponding 
to the mass of the holotoxin was recorded.  Reduced PDI was then perfused over 
the slide in the presence of 100 mM PBA.  PDI was present in the perfusion 
buffer until approximately 500 sec into the experiment, after which it was 
replaced with sequential additions of an anti-CTA antibody, an anti-PDI antibody, 




Figure 4-4 Effect of PBA on CT Translocation 
PBA does not inhibit the translocation of an ER-localized CTA1 construct.  CHO 
cells were transfected with a plasmid encoding a CTA1 subunit appended with an 
ER-targeting signal sequence.  Permeabilization of the plasma membrane with 
digitonin was used to partition cell extracts into separate organelle (pellet; P) and 
cytosolic (supernatant; S) fractions.  (A):  Both fractions from transfected cells 
were probed by Western blot to establish the distributions of Hsp90 and PDI.  
(B):  The distribution of CTA1 immunoprecipitated from transfected cells after a 1 
hr radiolabeling was visualized and quantified by SDS-PAGE with 
PhosphorImager analysis.  Experiments were performed with untreated cells and 
cells exposed to mM PBA.  The means ± SEMs of three independent 




Figure 4-5 Effect of PBA on CT Toxicity 
PBA inhibits CT intoxication.  (A):  HeLa cells were incubated with CT in the 
absence or presence of the stated PBA concentrations.  After two hours of 







The previous model for CTA1 translocation suggests that the A subunit is 
thermally stable and requires active unfolding in the ER to interact with the ERAD 
machinery.  It was originally thought that the trigger for this unfolding event was 
the C-terminal hydrophobic region of CTA1 (49).  However, recent work has 
shown that the C-terminal region of the toxin is not necessary for translocation to 
the cytosol (68).  We propose that the trigger for ERAD is the thermal instability 
of CTA1.  Our model suggests that CTA1 dissociation from the holotoxin results 
in the spontaneous unfolding of CTA1.  Unfolded proteins are what the ERAD 
machinery recognizes and eliminates from the ER.  Based on this model we 
predict that stabilization of the CTA1 structure would prevent translocation of the 
toxin to the cytosol.  Without an active A1 subunit of the toxin in the cytosol, there 
would be no harmful effects from the endocytosed toxin.   
 PBA stabilization prevented CTA1 from reaching a translocation 
competent state that could reach the cytosol.  Inhibition of translocation resulted 
in a decrease in toxicity.  These effects reveal the importance of thermal 
instability during the normal course of intoxication.  The supposed trigger for 
ERAD is not due to any particular domain of the toxin, but comes from a general 
loss of structure.  Stabilization results in a CTA1 that is not recognized as a 
misfolded protein by ERAD.  Without the aid of ERAD, CTA1 has no ability to 




4.4 Future Directions 
 
Exposure to a chemical chaperone such as 10% glycerol was never a viable 
therapeutic option.  PBA, on the other hand, is a FDA-approved chemical 
chaperone that will stabilize CTA1 in the ER and block translocation into the 
cytosol.  This suggests that PBA is a potential therapeutic for the treatment of CT 
intoxication and possibly other AB toxins.  Other ER-translocating toxins also 
appear to have thermally unstable A chains, so the stabilization of these subunits 
is a potential target for multi-toxin therapeutics.   The next direction in this study 
will be evaluating this drug for inhibition of other AB toxins.  PBA will also be 




CHAPTER 5  HSP90 IS REQUIRED FOR TRANSFER OF THE CHOLERA 




The commonly cited method of CTA1 escape from the ER requires CTA1 to 
refold itself on the cytosolic face of the ER (51).  This refolding of CTA1 in the 
cytosol is supposed to provide the driving force for extraction out of the ER.  
Recent CTA1 structural studies do not support this model, because the isolated 
CTA1 subunit will be unfolded at physiological temperature (57, 58, 69).  Without 
an innate stability, the molecular ratchet mechanism of self extraction is counter-
intuitive. 
Most ERAD substrates are extracted from the ER through a pathway that 
involves p97 (70).  However, p97 has been determined not to play any role in 
CTA1 dislocation (71, 72).  Since CTA1 maintains an unfolded conformation at 
37°C, some host protein must provide the driving force for CTA1 extraction from 
the ER.  This unidentified protein could possibly use refolding to drive the 
extraction process.  One possible candidate, Hsp 90 was observed to extract DT 
from the endosomes to the cytosol.  Hsp 90 has also been shown to maintain 
membrane-bound ERAD substrates in a soluble state and to decide the fate of 





5.2 Hsp90 binds to CTA1 
 
Hsp90 must bind directly to the A1 subunit of CT in order to be responsible 
for CTA1 extraction out of the ER.  To address this issue, SPR was used to 
determine whether Hsp90 could directly interact with the isolated CTA1 subunit 
at physiological temperature (Fig. 5-1).  Hsp90 binding to CTA1 occurred in an 
ATP-dependent manner that was blocked by geldanamycin (GA), a competitive 
inhibitor of the ATP binding pocket.  Hsp90 binds to CTA1 at 37°C.  Since CTA1 
is in an unfolded conformation at 37°C (22,24), this also suggested that Hsp90 
identifies CTA1 as an unfolded protein.  If Hsp90 is recognizing CTA1 as an 
unfolded protein then it could be attempting to refold CTA1 during the dislocation 
event.  Because GA affects both Hsp 90 and Grp94 both GA and NECA,a drug 
that only inhibits Grp 94, were used in order to differentiate whether any block in 
toxicity was due to Hsp 90 or Grp 94.  The interaction between CTA1 and Hsp90-
ATP was not substantially affected by NECA (Fig. 5-1).  The interaction between 
Hsp90 and CTA1 was much tighter than between GRP94 and CTA1 (Fig. 5-2 
and Table 5-1).  Consistent with the fact that both Hsp90 and GRP94 form 
dimers (73), both chaperones bound to CTA1 in a 2:1 ratio of chaperone:toxin 
(Fig. 5-2).  The specific, high-affinity interaction between Hsp90-ATP and CTA1 












Figure 5-1 Binding studies between CTA1 and Hsp 90 
GA but not NECA inhibits the interaction between CTA1 and Hsp90. Either 
Hsp90 (A) or GRP94 (B) was perfused over a CTA1-coated SPR sensor slide at 
37°C under the following conditions: no ATP in the perfusion buffer, ATP in the 
perfusion buffer, ATP and GA in the perfusion buffer, or ATP and NECA in the 
perfusion buffer. Ligand was removed from the perfusion buffer 240 sec into the 
experiment. One of four representative experiments is shown. In panel B, *** 




Figure 5-2 Hsp 90 binding affinity to CTA1 
Binding of CTA1 to Hsp90 or GRP94 (A): Hsp90 was perfused over a CTA1-
coated SPR sensor slide at 100, 400, 800, 1,600, and 3,200 nM concentrations. 
The ligand was removed from the perfusion buffer after 115 sec. (B): GRP94 was 
perfused over a CTA1-coated SPR sensor slide at 100, 200, 400, 800, and 1,600 
nM concentrations. The ligand was removed from the perfusion buffer after 118 
sec. Note that the results for Hsp90 and GRP94 are plotted on different scales. 
For all conditions, ATP was present in the 37°C perfusion buffer. The orange 
lines represent best fit curves derived from the raw data using 1:2 (CTA1:Hsp90 






CTA1 binding partner ka (1 / Ms) kd (1 / s) KD (nM) 
Hsp90 9,929 7.8 x 10-5 7 
GRP94 1,537 4.5 x 10-4 292  
TABLE 5-1 Calculations of cytosolic CTA1 
CTA1 exhibits a high affinity interaction with Hsp90 and a lower affinity 
interaction with GRP94.  On rates (ka), off rates (kd), and equilibrium dissociation 
constants (KD) between CTA1 and either Hsp90 or GRP94 were calculated from 

















5.3 Hsp90 is involved in cholera intoxication 
 
To detect a role for Hsp90 in CT intoxication, CT toxicity assays were 
performed in the presence or absence of GA (Fig. 5-3).  The elevated levels of 
cAMP resulting from CT intoxication were strongly inhibited in GA-treated cells.  
Whereas CT activity against untreated control cells exhibited a half-maximal 
effective concentration at 4 ng CT / ml, GA-treated cells only produced a third of 
the maximal cAMP response when they were treated with 100 ng CT / ml.  Thus, 
much more CT was be required to elicit the same amount of intoxication in GA-
treated cells as compared to control cells.  NECA-treated cells demonstrated the 
same level of sensitivity to CT as the untreated control cells (Fig. 5-3).  From this 
we conclude GA-induced toxin resistance is not a result of the inactivation of 
GRP94.  To ensure that our drug for knocking down the activity of Grp94 was 
active, we performed a control with NECA for ricin.  NECA-treated cells were 
resistant to ricin, another AB toxin that uses the ERAD system for A chain 
dislocation to the cytosol.  Control experiments demonstrated that GA did not 
block the activity of CTA1 expressed directly in the cytosol of cells transfected 
with a CTA1-encoding plasmid (52) (Fig 5-4).  Furthermore, GA did not inhibit 
forskolin, an adelyate cyclase agonist, from inducing elevation of cAMP.  This 







Figure 5-3 CTA1 Toxicity assay with Hsp 90 inhibitor present 
GA but not NECA inhibits CT intoxication. (A): CHO cells were incubated with 
varying concentrations of CT in the absence of additional treatment, in the 
presence of 0.1 μM GA, or in the presence of 0.1 μM NECA. After 2 hr of 
continual toxin exposure, toxicity was assessed from the elevated levels of 
intracellular cAMP. The means ± standard errors of the means (SEMs) of at least 






 Figure 5-4 GA does not affect the activity of cytosolic CTA1 
 
CHO cells were transfected with a plasmid encoding a CTA1 subunit that is 
expressed directly in the cytosol. Intracellular cAMP levels were then calculated 
at either 2 hrs (n = 1) or 4 hrs (n = 2) post-transfection for cells chased in the 





5.4 Hsp90 is responsible for the extraction of CTA1 out of the ER into the 
cytosol 
 
Toxin resistance can result from an inhibition of toxin progression out of the 
ER to the cytosol (28, 66, 74).  To determine if GA blocked toxin export to the 
cytosol, we utilized a dislocation assay (57, 75) to monitor the arrival of CTA1 to 
the cytosol (Fig. 5-5).  GA-treated HeLa cells were protected from CT in their 
cAMP production as they were in CHO cells.  The control experiment 
demonstrates that our selective permeabliization maintained the fidelity of 
membrane contained fractions and cytosolic fractions (Fig 5-5a).  Hsp 90 was 
used as a cytosolic marker and PDI was a marker for membrane encased 
soluble proteins.  Western blot analysis detected little or no PDI in the 
supernatant fraction.  Western blot analysis using non-reducing conditions was 
used to track the localization of CTA1 (Fig. 5-5b).  The 21 kDa CTA1 subunit is 
produced as part of a larger heterodimer.  Proteolytic cleavage of CTA creates a 
CTA1/CTA2 heterodimer, which has to be reduced in the ER. Only the smaller 
reduced CTA1 is able to enter into the cytosol.   Consisitent with this, our results 
detected both disulfide-linked CTA1/CTA2 and reduced CTA1 in the membrane 
fractions, but only found reduced CTA1 in the cytosol.  NECA treatment did not 
affect the distribution of CTA1 in the membrane bound fraction vs. the cytosolic 
fraction.  Treatment of cells with GA resulted in the accumulation of less cytosolic 
CTA1 than untreated or the cells treated with NECA.  It is thus apparent that 
Hsp90 function was required for the progression of CTA1 from the ER into the 
cytosol.    
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SPR was utilized to quantify the actual amount of CTA1 that reached the 
cytosol.  HeLa cells were pulse treated with CT at 4°C and were again 
fractionated into membrane contained and cytosol components after a 2 hour 
chase at 37°C.  The cytosolic fractions were introduced to a SPR sensor slide 
that had been coated with a CTA antibody (Fig. 5-5c).  There is a distinct 
relationship between the association constant determined by SPR and the 
concentration of the ligand present.  Using this relationship it is possible to 
calculate the concentration of CTA1 in cellular extracts from a translocation 
assay.  With this tool we determined the exact concentration of CTA1 that 
reaches the cytosol and also how that amount was decreased by the inhibition of 
Hsp90.  The amount of CTA1 we found in the cytosol of untreated cells was 
consistent with the inefficiency of the trafficking of cholera toxin from the cell 
surface to the ER.  The cells that were treated with NECA produced an SPR 
signal similar to that observed in control cells.   GA substantially reduced the 
SPR signal from cells that were exposed to CT (Table 5-2).   
To ensure that GA did not block the intracellular trafficking of CT, we 
screened media samples from toxin-treated cells for the presence of free CTA1.  
The reasoning for this experiment is that if we have secretion in one direction 
then trafficking is working in both directions.  In addition, a fraction of dissociated 
CTA1 enters the secretory pathway and is released into the extracellular medium 
(57, 60).  Consistent with these observations, our SPR assay detected the 
secretion of CTA1 from intoxicated HeLa cells (Fig. 5-5d).  Nearly equivalent 
amounts of CTA1 were secreted into the medium of untreated cells and cells 
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treated with GA.  No signal was obtained from the medium of BfA-treated cells, 
thus demonstrating that toxin trafficking to the ER was a prerequisite for CTA1 
secretion into the medium.  Secreted toxin was free CTA1 and not the CT 
holotoxin because CT has a KDEL retention tag and once that is removed CTA1 
can be secreted if stabilized.  Since untreated and GA-treated cells released 
equivalent amounts of free CTA1, GA did not appear to block holotoxin trafficking 
to the ER, CTA1 dissociation from the rest of the toxin in the ER, or the secretion 
of free CTA1.  
The block of toxicity or the drop in cytosolic CTA1 could be a by product 
of Hsp90 activity.  To address these concerns we combined our dislocation 
assay with a plasmid-based system to express CTA1 directly in the ER of 
transfected CHO cells (65) in order to ensure that blocking Hsp 90 did not affect 
any up stream trafficking step.  CTA1 is co-translationally inserted into the ER 
and then dislocated back to the cytosol.  This strategy has been used by other 
labs to monitor toxin progression to the cytosol (75-80).  Control experiments 
again demonstrated the fidelity of our fractionation protocol (Fig. 5-6a).  
Consistent with the SPR-based dislocation assay, which used exogenously 
applied toxin, this plasmid-based system detected a block of CTA1 dislocation to 
the cytosol, in GA-treated cells (Fig. 5-6b).  Little or no effect on CTA1 dislocation 
was found for NECA-treated cells(Fig. 5-6).    
It is common to have drug treatments to have unexpected effects either 
up or downstream from your point of refrence. To address this we utilized RNAi.  
We knocked down only Hsp 90 by RNAi  and we repeated the toxicity assay to 
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show that the results that we have demonstrated come from a loss of Hsp 90 
activity alone (Fig. 5-7).   
Toxin turnover could be responsible for this drop in toxicity for GA treated 
cells.  Very little toxin, that binds to the cell surface, actually progress to the ER 
for translocation.  If Hsp90 is affecting the turnover of cytosolic toxin, then the 
loss of toxicity and observed translocation could be an artifact.  To address this 
issue we utilized our SPR translocation assay with the addition of proteasome 
inhibitors (Fig. 5-8).  Blocking the activity of Hsp90 with GA did not affect the 
accumulation of CTA1 in the cytosol also demonstrating that the activity of Hsp90 




























Figure 5-5 Effect of the loss of Hsp 90 on CTA1 Translocation 
GA but not NECA inhibits CTA1 dislocation to the cytosol. HeLa cells were 
pulselabeled at 4°C for 30 min with 1 μg / ml of CT. The cells were then chased 
for 2 hr at 37°C in toxin-free medium containing no additions, 0.1 μM GA, 0.1 μM 
NECA, or 5 μg / ml of BfA. (A): Both fractions from untreated cells were probed 
by Western blot to establish the distributions of cytosolic marker Hsp90 and ER 
marker PDI. (B)The upper band represents the disulfide linked CTA1/CTA2 
heterodimer; the middle band results from non-specific cross-reactivity; and the 
lower band represents reduced CTA1. (C): An SPR sensor slide coated with an 
anti-CTA antibody was used to detect the cytosolic pool of CTA1 from untreated 
or drug-treated cells. (D): Media samples taken from cells at the end of the chase 
were perfused over an SPR sensor slide coated with an anti-CTA antibody.  For 
both (C) and (D), CTA standards were perfused over the sensor slide as positive 
controls. The cytosolic fraction and medium from unintoxicated cells were also 
perfused over the sensor slides as negative controls for panels (C) and (D), 
respectively. At the end of each experiment, bound sample was stripped from the 




Figure 5-6 Effect of the loss of Hsp 90 on translocation of CTA1 into the 
cytosol 
GA inhibits dislocation of an ER-localized CTA1 construct. CHO cells were 
transfected with a plasmid encoding a CTA1 subunit appended with an ER-
targeting signal sequence. Permeabilization of the plasma membrane with 
digitonin was used to partition cell extracts into separate organelle (pellet; P) and 
cytosolic (supernatant; S) fractions. (A): Both fractions from transfected cells 
were probed by Western blot to establish the distributions of Hsp90 and PDI. (B): 
The distribution of CTA1 immunoprecipitated from transfected cells after a 1 hr 
radiolabeling was visualized and quantified by SDS-PAGE with PhosphorImager 
analysis. Experiments were performed with untreated control cells, cells exposed 
to 0.1 μM NECA, or cells exposed to 0.1 μM GA. The upper band in the gel 
represents the population of CTA1 with an intact, uncleaved signal sequence. 





 Ligand Association rate 
constant (1/Ms)  
 
Calculated quantity 
0.1 ng CTA standard  13,066   0.15 ng 
1 ng CTA standard  24,753   0.45 ng 
10 ng CTA standard  61,976   14 ng 
100 ng CTA standard  83,668   104 ng 
No treatment sample  17,064   0.22 ng 
+ NECA sample  17,925   0.24 ng 
+ GA sample  7,524   0.09 ng 
Mock RNAi  15,373   0.19 ng 
Control RNAi  14,890   0.18 ng 
Hsp90 RNAi 3,489   0.06 ng 
 
TABLE 5-2 Calculations of cytosolic CTA1 
 Association rate constants were calculated from the SPR data presented in 
Figures 5-4C. The association rate constants for the CTA standards were plotted 
as a function of protein quantity, and the slope of the resulting standard curve 











Figure 5-7 Effect of the loss of Hsp 90 on CT toxicity 
Transfected cells were exposed to varying concentrations of CT for 2 hr before 
intracellular cAMP levels were determined. The means ± SEMs of 4 independent 







 Figure 5-8 Proteasome inhibition does not affect the accumulation of 
cytosolic CTA1 
 
HeLa cellswere pulse-labeled at 4C for 30 min with 1 g / ml of CT. The cells were 
then chased for 2 hr at 37C in toxin-free medium that contained no additions, 100 
M ALLN, 100 M MG132, 0.1 M GA, 0.1 M GA & 100 M ALLN, or 0.1 M GA & 100 
M MG132. Selective permeabilization of the plasma membrane with digitonin 
was used to partition cell extracts into separate organelle and cytosolic fractions. 
An SPR sensor slide coated with an anti-CTA antibody was used to detect the 
cytosolic pool of CTA1 from untreated (no treatment) or drug-treated cells. CTA 
standards were perfused over the sensor slide as positive controls. In the time 
frame of this 2 hr pulse-chase experiment, inhibition of the proteasome with 
ALLN or MG132 did not alter the level of cytosolic CTA1 in either untreated or 
GA treated cells. The disruption of proteasome function was confirmed with an 
assay that detected an inhibition of bulk protein turnover in radiolabeled cells 





Recently, Hsp90 was shown to be involved with the refolding of an 
exogenously added protein that progressed from the cell surface to the ER and 
from the ER to the cytosol (81).  Hsp90 in that study assisted the refolding of the 
unfolded, exogenously added protein.  This activity may be linked to the 
dislocation activity of Hsp 90.  It is not a stretch to couple dislocation with 
refolding.  Hsp90 would extract CTA1 from the ER by refolding CTA1, thus 
preventing CTA1 from returning into the translocation pore.  This extraction 
would thus provide the driving force for CTA1 dislocation.  Although a previous 
report suggested the ATP-dependent translocation of CTA1 does not require 
cytosolic factors (76), we and others (75, 82) have detected a membrane-
associated pool of Hsp90 which could easily been present in those previous 
studies.  Our work clearly shows that Hsp90 maintains a high affinity interaction 
with CTA1, and that blocking of this interaction inhibits both CTA1 dislocation and 
CT intoxication in vivo.   
ERAD substrates are usually exported to the cytosol through the action of 
p97 (70, 83).  However, there is also a p97-independent dislocation route for 
some ERAD substrates such as CTA1 (71, 72, 84, 85).  This work demonstrates 
that the p97-independent dislocation of CTA1 requires Hsp90 function.  We have 
thus established a new role for Hsp90 in the extraction of a soluble ERAD 




CHAPTER 6 GENERAL DISCUSSION 
 
Many AB protein toxins are category B agents on the CDC list of bio-
terrorism agents. Many AB toxins are also commonly associated with food- or 
waterborne disease.  While antibiotics are available to treat some of the 
infections, prevention of toxin action is an ideal target for alternate therapeutic 
approaches.  AB toxins all face the same problem.  They all bind to the cell 
surface and must cross a membrane barrier to reach their cytosolic target.  Some 
of the AB toxins utilize ERAD to translocate into the cytosol.  The use of one 
pathway by so many toxins makes ERAD an ideal candidate for a therapeutic 
target. Understanding the cell biology of intoxication will thus help to develop 
novel, possibly broad spectrum, treatments for intoxication.   
 Our study began with the investigation of PDI and its role on cholera 
intoxication. Within the ER, PDI serves to dislodge the A1 active subunit from the 
rest of the holotoxin.  Upon binding, PDI serves as nothing more than a wedge to 
pry the active subunit of the toxin out of association with the rest of the holotoxin 
where it is stably held.  CTA1, without the stabilizing effect of the holotoxin, 
spontaneously unfolds and becomes a normal candidate for ERAD-mediated 
translocation out of the ER.  Our results contradict one of the most cited and 
entrenched ideas in toxin trafficking, that PDI is an unfoldase.  The disruption of 
PDI function results in decreased toxicity, confirming our initial hypothesis that 
PDI is necessary for toxicity via holotoxin disassembly, but not for CTA1 
unfolding.  This insight gives a potential therapeutic target, as stabilization of 
CTA1 disrupts CT intoxication. 
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CT arrival in the ER triggers a series of events that results in CTA1 dissociation 
from the rest of the holotoxin resulting in a shift in CTA1 structure to a partially 
unfolded conformation.  This partially unfolded conformation triggers export from 
the ER to the cytosol, where CTA1 can act upon its cytosolic target.  Here we 
showed that stabilization of the CTA1 structure with PBA indeed prevented both 
the translocation event and intoxication.  PBA represented a prime candidate for 
blocking CT toxicity by stabilizing CTA1 in the ER, thereby removing its ability to 
gain entry into the cytosol.  Unlike other chemical chaperones that have been 
tested, PBA is commercially available, FDA approved, and generally well 
tolerated.  These PBA results confirms that stabilization of the A subunit of CT in 
the ER will result in a loss of toxicity. 
  Toxicity not only requires that the A subunit of CT achieves a 
translocation- competent conformation to gain entry into the cytosol, it also must 
have an active translocate force to move out of the ER.  For normal ERAD 
substrates P97 is responsible for this active extraction, but studies have shown 
that CTA1 is not acted on by p97.  This extraction must therefore be carried out 
by another protein or protein complex.  Hsp 90 is a cytosolic chaperone that has 
been linked to the extraction of AB toxins from the endosomes into the cytosol.  It 
has also has been located on the cytosolic face of the ER lumen.  We 
demonstrate that Hsp 90 is required for this extraction of CTA1 out of the ER into 
the cytosol.  Blocking the activity of Hsp90 results in a loss of toxicity for CT.  
This loss of toxicity is due to its inability to translocate across the ER membrane.
 Based on the collective results presented here, we have suggested an 
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alternative to the current model of CTA1 translocation.  It is currently believed 
that CTA1 is a thermally stable protein that is actively unfolded in the ER by PDI.  
We have shown that CTA1 attains an unfolded conformation at 37°C in the 
absence of PDI.  We have further shown that stabilization of CTA1 structure 
disrupts the ERAD the translocation event and intoxication.  We have also shown 
that there is no toxicity without an active cytosolic partner to extract the 
translocation competent CTA1.   
 This study demonstrates that CTA1 is stable only in association with the 
holotoxin.  When PDI removes this stabilization, CTA1 will unfold.  Stabilization of 
CTA1 by chemical chaperone PBA will keep CTA1 from achieving a 
translocation-competent state.  CTA1 will therefore be stuck in the ER until it is 
degraded.  Achieving a translocation-competent state is not enough for CTA1 to 
gain exit from the ER; the cytosolic chaperone Hsp90 must also act to extract 
CTA1 from the ER into the cytosol.  These collective observations form the basis 
for a new, substantially different model of CTA1 translocation. 
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